Moreover, tumor‐bearing mice lacking the CXCL9 receptor CXCR3 show poor responses to anti‐PD1 treatment, suggesting that CXCL9 production by cDC1s is essential for facilitating the tumor immune response. The gene discussed is CXCL9; the disease is neoplasm.